

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

PROFIT WARNING

This announcement is made by MicroPort Scientific Corporation (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors of the Company that the Group, based on the preliminary assessment of the Group’s latest unaudited consolidated management accounts and the information currently available to the Group, is expected to record a consolidated loss for the three months ended 31 March 2014 as compared to a consolidated profit of the corresponding period in 2013. Such expected loss is mainly attributable to the one-off transitional expenses which involve integration activities in relation to the acquisition of the OrthoRecon business from Wright Medical Group, Inc. (NASDAQ:WMGI) and the net loss attributable to the OrthoRecon business for the three months ended 31 March 2014. The transitional expenses are non-recurring in nature and primary comprise of re-branding and re-licensing costs of the OrthoRecon products as well as other related legal and professional costs.

The Board is of the view that it is common for acquired business to incur additional costs and expenses during their early stages of integration into the Group and that the current one-off transitional expenses are at level acceptable to the Company. Without taking into consideration the one-off transitional expenses and the net loss attributable to the new OrthoRecon business, the non-OrthoRecon businesses of the Group recorded a growth in net profit for the three months ended 31 March 2014 as compared with the corresponding period in 2013.

The information contained in this announcement is based on the information currently available to the Group and the preliminary assessment of the latest unaudited consolidated management accounts of the Group prepared by the management of the Company, which have not been audited or reviewed by the Company's auditors. Further details of the Group's financial information will be disclosed in the interim results of the Group for the six months ended 30 June 2014 which will be announced in August 2014.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Hong Kong, 17 June 2014

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida and Mr. Hiroshi Shirafuji; and the independent non-executive Directors are Mr. Zezhao Hua, Mr. Jonathan H. Chou and Dr. Guoen Liu.

* *for identification purpose only*